Image source: shutterstock.com

Highlights

  • Smith & Nephew PLC is a medical technology company with operations across the globe.
  • The company marked Q2 FY23 with a significant growth across all three franchises.
  • In H1 FY23, Smith & Nephew’s top line business witnessed a 7% year-on-year growth.
  • Smith & Nephew has announced to pay an interim dividend of 14.40 US cents per share in November 2023.

FTSE 100 listed Smith & Nephew PLC (LSE: SN.) is a medical technology company with operations across the globe. Started in 1856 in Hull, United Kingdom, the Group is presently spread across 100 countries with a workforce of over 17,500 employees.

The company marked the second quarter of FY23 with a significant growth across all three franchises. However, its Orthopaedics segment delivered higher productivity.

In the first half of the fiscal year 2023, Smith & Nephew’s top line business witnessed a 6.7% year-on-year growth. Its operating profit increased 13.6% YoY for the reporting period.

In H1 FY23, the company launched 13 new products, mainly in high growth segments like shoulder replacement, robotics, and negative pressure wound therapy.

Smith & Nephew has announced to pay an interim dividend of 14.40 US cents per share in November 2023, with the ex-dividend date of 05 October 2023.

For the mid-term, the firm is targeting a 5% surge in revenue, based on the return on innovation investments and execution of 12-point plan. Moreover, the trading profit margin expansion is likely to be minimum 20% in FY25 because of enhanced productivity.

For the full year FY23, Smith & Nephew is expecting 6.0 to 7.0% growth in underlying revenue. Its trading profit margin is likely to be minimum 17.5% for the year.

Top 10 Shareholders

Around 22.76% of the total shareholdings are owned by the top ten shareholders of the firm. While BlackRock Institutional Trust Company, N.A. holds approximately 5.32% shareholding, the Vanguard Group, Inc. holds 3.25% shareholding in Smith & Nephew.

Stock price Performance

The company’s stock price has dropped by almost 6.71% in the last one month. It has decreased around 11.65% over the last six months. The stock’s 52-week low and high price stand at GBX 959.20 and GBX 1,316.75, respectively.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 27 September 2023. The reference data in this report has been partly sourced from EODHD/Others.